Antiepileptik ilaçların serum lipid değerlerine etkisi

References (9)

1. Elger C, Schmidt D. Modern management of epilepsy: a practical approach. Epilepsy Behav 2008; 12: 501-39
2. Isorjarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579-84
3. Rattya J, Pakarinen AJ, Turkka J, Kotila M, Rattya J, Myllyla VV, Isorjarvi JI. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001; 57: 440-4
4. Newman WP, Friedman DS, Voors AW. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. New Engl J Med 1986; 314: 138-44
5. Muuronen A, Kaste M, Nikkila EA, Tolppanen EM. Mortality from ischemic heart disease among the patients using anticonvulsant drugs: a case control study. BMJ 1985; 291: 1481-3
6. Eiris JM, Rodriguez IN, Rio MD, Mesegaer P, Rio MC, Gago MC. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000; 41: 1-7
7. Demircioğlu S, Soylu A, Diric E. Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children. Pediatr Neurol 2000; 23: 142-146
8. Zeilthoper S, Doppelbauer A, Tribl G, Leitha T, Deecke L. Chnages in serum lipid pattern during long term anticonvulsant treatment. Clin Invest 1993; 71: 574-578
9. Kurt S, Karaer H, Kaplan Y. Epilepsili hastalarda karbamazepin ve okskarbazepin tedavisinin serum lipid düzeylerine etkisi. Nöropsikiyatri arşivi 2008; 45: 32-6.